IRF4重排大B细胞淋巴瘤的独特分子特征
该研究对31例DLBCL-NOS、20例LBCL-IRF4和12例HGBCL-NOS的25岁及以下患者进行靶向基因测序、拷贝数阵列和基因表达谱分析,发现各亚组分子特征不同;LBCL-IRF4常见IRF4和NF-κB通路基因突变及特定拷贝数异常,DLBCL-NOS以GCB亚型为主且突变谱类似成人,HGBCL-NOS部分病例有Burkitt样基因改变;不良预后因素包括年龄>18岁、ABC DLBCL、HGBCL-NOS、高遗传复杂性及特定拷贝数异常和TP53、MYC突变。
要点
- LBCL-IRF4具有独特分子谱:IRF4和NF-κB通路基因突变、17p13缺失及7、11q12.3-q25等增益。
- DLBCL-NOS以GCB亚型为主,突变谱类似成人(SOCS1、KMT2D),伴2p16/REL增益和19p13/CD70缺失。
- 不良预后因素包括年龄>18岁、ABC DLBCL、HGBCL-NOS、高遗传复杂性及1q21-q44增益等。
核心结论
- 儿童和年轻成人LBCL各亚组具有不同分子特征,LBCL-IRF4有独特分子谱。
- 研究结果有助于改进该类肿瘤分类并提供风险分层新参数。
研究设计与样本
- 研究纳入31例DLBCL-NOS、20例LBCL-IRF4和12例HGBCL-NOS的25岁及以下患者。
- 采用靶向基因测序、拷贝数阵列和基因表达谱分析的综合方法。
主要发现
- LBCL-IRF4常有IRF4和NF-κB通路基因(CARD11、CD79B、MYD88)突变,17p13缺失,7号染色体、11q12.3-q25增益。
- DLBCL-NOS以GCB亚型为主,携带类似成人的基因突变(如SOCS1和KMT2D),2p16/REL增益,19p13/CD70缺失。
- 部分HGBCL-NOS显示Burkitt淋巴瘤相关基因(MYC、ID3、DDX3X)反复改变和9p21/CDKN2A纯合缺失,其他病例遗传上更接近GCB DLBCL。
- 不良预后因素包括年龄>18岁、ABC DLBCL谱、HGBCL-NOS、高遗传复杂性、1q21-q44增益、2p16/REL增益/扩增、19p13/CD70纯合缺失以及TP53和MYC突变。
临床怎么用
- 对年轻LBCL患者可结合分子检测识别LBCL-IRF4等亚型,辅助分类。
- 评估不良预后因素(如年龄>18岁、ABC亚型、HGBCL-NOS、高遗传复杂性及特定拷贝数异常和TP53、MYC突变)有助于风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric large B-cell lymphomas (LBCLs) share morphological and phenotypic features with adult types but have better prognosis. The higher frequency of some subtypes such as LBCL with IRF4 rearrangement (LBCL-IRF4) in children suggests that some age-related biological differences may exist. To characterize the genetic and molecular heterogeneity of these tumors, we studied 31 diffuse LBCLs (DLBCLs), not otherwise specified (NOS); 20 LBCL-IRF4 cases; and 12 cases of high-grade B-cell lymphoma (HGBCL), NOS in patients ≤25 years using an integrated approach, including targeted gene sequencing, copy-number arrays, and gene expression profiling. Each subgroup displayed different molecular profiles. LBCL-IRF4 had frequent mutations in IRF4 and NF-κB pathway genes (CARD11, CD79B, and MYD88), losses of 17p13 and gains of chromosome 7, 11q12.3-q25, whereas DLBCL, NOS was predominantly of germinal center B-cell (GCB) subtype and carried gene mutations similar to the adult counterpart (eg, SOCS1 and KMT2D), gains of 2p16/REL, and losses of 19p13/CD70. A subset of HGBCL, NOS displayed recurrent alterations of Burkitt lymphoma-related genes such as MYC, ID3, and DDX3X and homozygous deletions of 9p21/CDKN2A, whereas other cases were genetically closer to GCB DLBCL. Factors related to unfavorable outcome were age >18 years; activated B-cell (ABC) DLBCL profile, HGBCL, NOS, high genetic complexity, 1q21-q44 gains, 2p16/REL gains/amplifications, 19p13/CD70 homozygous deletions, and TP53 and MYC mutations. In conclusion, these findings further unravel the molecular heterogeneity of pediatric and young adult LBCL, improve the classification of this group of tumors, and provide new parameters for risk stratification.
引用
- Ramis-Zaldivar JE, Gonzalez-Farré B, Balagué O, et al. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood. 2020. PMID: 31738823. doi:10.1182/blood.2019002699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。